Between the mid-1990s and now, median overall survival for men with metastatic castrate resistant prostate cancer (CRPC) starting on chemotherapy has risen from 1 year to almost 3 years. This review summarizes progress made over the last 2 decades in the systemic management of patients with CRPC and evolving treatment directions.
|Number of pages||6|
|Publication status||Published - 1 Aug 2014|
- Androgen deprivation therapy
- Androgen receptor antagonist
- Bone-targeted therapy
- Metastatic castration-resistant prostate cancer
- Predictive biomarker